PLX.US Protalix Biotherapeutics Inc

Healthcare Biotechnology USA Stocks
2.88 USD
Close of Nov 18, 2026
1.65 3.19
Market cap
USD 243M
P/E
12.0x
P/B
3.17x
ROE
43.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is PLX.US undervalued?

Graham number
Price2.88
Graham value2.21
Premium30.1%

PLX.US trades 30.1% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Protalix Biotherapeutics Inc fundamental analysis

No fundamental analysis for Protalix Biotherapeutics Inc yet.

Protalix Biotherapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Protalix Biotherapeutics Inc

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which i…

Full company profile